Growth hormone water injection, a new biological drug of Anke, is expected to enter the field inspection within this year

The growth hormone water injection (i.e recombinant human growth hormone injection) has been progressing smoothly since the application for production approval in August last year, and the company is striving to enter the site for inspection within this year, according to an insider of the company Generally speaking, after the new drug enters the field inspection, if everything goes well, it is expected to obtain the production approval within half a year According to the insider, at present, the application of water needle is in an orderly progress, and the existing biological preparation workshop can be used to produce water needle in the future, "now it only depends on the speed of approval" Recombinant human growth hormone (rhGH) is one of the main biological products of Anke biology Its freeze-dried powder injection type has been on the market for many years and keeps a high growth Recombinant human growth hormone injection is a new dosage form developed on the basis of this variety, which has the characteristics of convenient use and strong market competitiveness The company said that it is a trend to replace powder injection with water injection in the future, but it will exist at the same time for a long time After the approval of water injection, the company has gained greater growth space At present, only Jinsai pharmaceutical, a subsidiary of Changchun hi tech (000661 SZ), is producing and selling recombinant human growth hormone injection in China According to the annual report data of Anke biology, the company's growth hormone sales revenue in 2014 was about 150 million, with a year-on-year growth of more than 35% Some analysts estimate that the growth rate of growth hormone will still exceed 35% in the next two years, especially after the approval of water injection, the growth rate of growth hormone series will be accelerated.